Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1B Rare Disease Deal
Italian pharmaceutical company Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for approximately $4.1 billion in cash. The deal, valued...
Italian pharmaceutical company Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for approximately $4.1 billion in cash. The deal, valued...
Kelonia Therapeutics, a CAR-T biotech on the brink of collapse three times, was acquired by Eli Lilly for $3.25 billion. The deal highlights the secto...